Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.19 USD | +3.26% |
|
+6.68% | +15.82% |
06-28 | Mirum Pharmaceuticals Submits New Drug Application for Cholesterol Metabolism Treatment | MT |
06-20 | Stifel Adjusts Mirum Pharmaceuticals Price Target to $66 From $48, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.82% | 1.61B | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals Submits New Drug Application for Cholesterol Metabolism Treatment